The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The investigational oral remedy KTX-1001, often known as gintemetostat, is catching curiosity as a possible therapy for a subgroup of sufferers with...
Therapy with relacorilant plus Abraxane (nab-paclitaxel) could provide a broader choice for sufferers with platinum-resistant ovarian most cancers as a result of...
Dr. Suneel Kamath, a gastrointestinal medical oncologist at Cleveland Clinic in Ohio and an assistant professor of medication on the Cleveland Clinic...
Ongoing monitoring stays a cornerstone of survivorship take care of sufferers with most cancers, serving to detect recurrence early and establish delayed...
